Drug Trial Radar · NCT04829916
A Study to Evaluate RMC-035 in Subjects Undergoing Cardiac Surgery
Last checked: Nov 19, 2026Latest source record: Apr 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Mar 16, 2021
Primary completion
Jul 15, 2021
Study completion Jul 15, 2021
Sponsor
- Lead sponsor
- Guard Therapeutics ABIndustry
- Sponsor type
- Industry
- First posted
- Apr 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the clinical study is to assess safety, tolerability and pharmacokinetics of RMC-035 for the prevention and treatment of acute kidney injury (AKI) in patients undergoing cardiac surgery.
Conditions
- Acute Kidney Injury (AKI)
Interventions
RMC-035Drug
Multiple dosing during 48 hours following cardiac surgery
PlaceboDrug
Multiple dosing during 48 hours following cardiac surgery
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of Adverse Events (AEs)Time frame: Baseline through day 30
- Severity of AEsTime frame: Within 4 days from first dose of IMP
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Münster University Hospital
Münster, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.